Literature DB >> 9399896

Human phenylalanine hydroxylase mutations and hyperphenylalaninemia phenotypes: a metanalysis of genotype-phenotype correlations.

E Kayaalp1, E Treacy, P J Waters, S Byck, P Nowacki, C R Scriver.   

Abstract

We analyzed correlations between mutant genotypes at the human phenylalanine hydroxylase locus (gene symbol PAH) and the corresponding hyperphenylalaninemia (HPA) phenotypes (notably, phenylketonuria [OMIM 261600]). We used reports, both published and in the PAH Mutation Analysis Consortium Database, on 365 patients harboring 73 different PAH mutations in 161 different genotypes. HPA phenotypes were classified as phenylketonuria (PKU), variant PKU, and non-PKU HPA. By analysis both of homoallelic mutant genotypes and of "functionally hemizygous" heteroallelic genotypes, we characterized the phenotypic effect of 48 of the 73 different, largely missense mutations. Among those with consistent in vivo expression, 24 caused PKU, 3 caused variant PKU, and 10 caused non-PKU HPA. However, 11 mutations were inconsistent in their effect: 9 appeared in two different phenotype classes, and 2 (I65T and Y414C) appeared in all three classes. Seven mutations were inconsistent in phenotypic effect when in vitro (unit-protein) expression was compared with the corresponding in vivo phenotype (an emergent property). We conclude that the majority of PAH mutations confer a consistent phenotype and that this is concordant with their effects, when known, predicted from in vitro expression analysis. However, significant inconsistencies, both between in vitro and in vivo phenotypes and between different individuals with similar PAH genotypes, reveal that the HPA-phenotype is more complex than that predicted by Mendelian inheritance of alleles at the PAH locus.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9399896      PMCID: PMC1716084          DOI: 10.1086/301638

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  57 in total

1.  Phenylketonuria--genotypes and phenotypes.

Authors:  C R Scriver
Journal:  N Engl J Med       Date:  1991-05-02       Impact factor: 91.245

2.  Phenylketonuria missense mutations in the Mediterranean.

Authors:  Y Okano; T Wang; R C Eisensmith; R Longhi; E Riva; M Giovannini; R Cerone; C Romano; S L Woo
Journal:  Genomics       Date:  1991-01       Impact factor: 5.736

3.  Novel missense mutation in the phenylalanine hydroxylase gene leading to complete loss of enzymatic activity.

Authors:  I Dianzani; P M Knappskog; L de Sanctis; S Giannattasio; E Riva; A Ponzone; J Apold; C Camaschella
Journal:  Hum Mutat       Date:  1995       Impact factor: 4.878

4.  Phenylketonuria in southern Poland: a new splice mutation in intron 9 at the PAH locus.

Authors:  M Zygulska; A Eigel; J J Pietrzyk; J Horst
Journal:  Hum Mutat       Date:  1994       Impact factor: 4.878

5.  Different phenotypic manifestations associated with identical phenylketonuria genotypes in two Spanish families.

Authors:  B Pérez; L R Desviat; M J García; M Ugarte
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

6.  Phenylalanine hydroxylase genotypes, predicted residual enzyme activity and phenotypic parameters of diagnosis and treatment of phenylketonuria.

Authors:  P Burgard; A Rupp; D S Konecki; F K Trefz; H Schmidt; U Lichter-Konecki
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

7.  Expression of rat liver phenylalanine hydroxylase in insect cells and site-directed mutagenesis of putative non-heme iron-binding sites.

Authors:  B S Gibbs; D Wojchowski; S J Benkovic
Journal:  J Biol Chem       Date:  1993-04-15       Impact factor: 5.157

8.  Characterization of phenylketonuria alleles in the Italian population.

Authors:  I Dianzani; S Giannattasio; L de Sanctis; C Alliaudi; P Lattanzio; C Dionisi Vici; A Burlina; M Burroni; G Sebastio; F Carnevale
Journal:  Eur J Hum Genet       Date:  1995       Impact factor: 4.246

9.  Delineation of the catalytic core of phenylalanine hydroxylase and identification of glutamate 286 as a critical residue for pterin function.

Authors:  P W Dickson; I G Jennings; R G Cotton
Journal:  J Biol Chem       Date:  1994-08-12       Impact factor: 5.157

10.  Non-phenylketonuria hyperphenylalaninaemia in Northern Ireland: frequent mutation allows screening and early diagnosis.

Authors:  J Zschocke; C A Graham; F J Stewart; D J Carson; N C Nevin
Journal:  Hum Mutat       Date:  1994       Impact factor: 4.878

View more
  44 in total

Review 1.  Defective folding and rapid degradation of mutant proteins is a common disease mechanism in genetic disorders.

Authors:  N Gregersen; P Bross; M M Jørgensen; T J Corydon; B S Andresen
Journal:  J Inherit Metab Dis       Date:  2000-07       Impact factor: 4.982

Review 2.  The role of chaperone-assisted folding and quality control in inborn errors of metabolism: protein folding disorders.

Authors:  N Gregersen; P Bross; B S Andrese; C B Pedersen; T J Corydon; L Bolund
Journal:  J Inherit Metab Dis       Date:  2001-04       Impact factor: 4.982

3.  Protein stability and in vivo concentration of missense mutations in phenylalanine hydroxylase.

Authors:  Zhen Shi; Jenn Sellers; John Moult
Journal:  Proteins       Date:  2011-09-21

4.  Missense mutations in the N-terminal domain of human phenylalanine hydroxylase interfere with binding of regulatory phenylalanine.

Authors:  T Gjetting; M Petersen; P Guldberg; F Güttler
Journal:  Am J Hum Genet       Date:  2001-04-20       Impact factor: 11.025

5.  Mutation analysis of PAH gene in patients with PKU in western Iran and its association with polymorphisms: identification of four novel mutations.

Authors:  Reza Alibakhshi; Keyvan Moradi; Zahra Mohebbi; Keyghobad Ghadiri
Journal:  Metab Brain Dis       Date:  2013-09-19       Impact factor: 3.584

6.  Missense variants in CFTR nucleotide-binding domains predict quantitative phenotypes associated with cystic fibrosis disease severity.

Authors:  David L Masica; Patrick R Sosnay; Karen S Raraigh; Garry R Cutting; Rachel Karchin
Journal:  Hum Mol Genet       Date:  2014-12-08       Impact factor: 6.150

7.  Tetrahydrobiopterin monotherapy for phenylketonuria patients with common mild mutations.

Authors:  Robert Steinfeld; Alfried Kohlschütter; Johannes Zschocke; Martin Lindner; Kurt Ullrich; Zoltan Lukacs
Journal:  Eur J Pediatr       Date:  2002-07       Impact factor: 3.183

Review 8.  What we know that could influence future treatment of phenylketonuria.

Authors:  C N Sarkissian; A Gámez; C R Scriver
Journal:  J Inherit Metab Dis       Date:  2008-08-03       Impact factor: 4.982

9.  Phenylketonuria: an inborn error of phenylalanine metabolism.

Authors:  Robin A Williams; Cyril D S Mamotte; John R Burnett
Journal:  Clin Biochem Rev       Date:  2008-02

10.  Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency.

Authors:  B S Andresen; S Olpin; B J Poorthuis; H R Scholte; C Vianey-Saban; R Wanders; L Ijlst; A Morris; M Pourfarzam; K Bartlett; E R Baumgartner; J B deKlerk; L D Schroeder; T J Corydon; H Lund; V Winter; P Bross; L Bolund; N Gregersen
Journal:  Am J Hum Genet       Date:  1999-02       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.